BlackRock
HRMY icon

BlackRock’s Harmony Biosciences HRMY Stock Holding History

BlackRock’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259M Buy
7,101,965
+31,930
+0.5% +$1.01M ﹤0.01% 1635
2026
Q1 		$198M Sell
7,070,035
-18,653
-0.3% -$612K ﹤0.01% 1674
2025
Q4 		$265M Buy
7,088,688
+162,746
+2% +$5.35M ﹤0.01% 1502
2025
Q3 		$191M Buy
6,925,942
+189,003
+3% +$6.51M ﹤0.01% 1687
2025
Q2 		$213M Buy
6,736,939
+225,066
+3% +$7.24M ﹤0.01% 1594
2025
Q1 		$216M Sell
6,511,873
-456,224
-7% -$16.4M ﹤0.01% 1560
2024
Q4 		$240M Buy
6,968,097
+1,312,107
+23% +$45.1M ﹤0.01% 1571
2024
Q3 		$226M Sell
5,655,990
-179,253
-3% -$6.3M ﹤0.01% 1585
2024
Q2 		$176M Sell
5,835,243
-87,518
-1% -$2.63M ﹤0.01% 1689
2024
Q1 		$199M Sell
5,922,761
-80,566
-1% -$2.59M ﹤0.01% 1654
2023
Q4 		$194M Sell
6,003,327
-129,160
-2% -$3.61M ﹤0.01% 1666
2023
Q3 		$201M Buy
6,132,487
+382,009
+7% +$13.3M 0.01% 1547
2023
Q2 		$202M Buy
5,750,478
+790,338
+16% +$27.3M 0.01% 1571
2023
Q1 		$162M Buy
4,960,140
+90,358
+2% +$4.11M ﹤0.01% 1699
2022
Q4 		$268M Buy
4,869,782
+67,669
+1% +$3.72M 0.01% 1315
2022
Q3 		$213M Buy
4,802,113
+829,234
+21% +$40.4M 0.01% 1429
2022
Q2 		$194M Buy
3,972,879
+139,960
+4% +$6.3M 0.01% 1557
2022
Q1 		$186M Buy
3,832,919
+93,153
+2% +$3.8M 0.01% 1724
2021
Q4 		$159M Buy
3,739,766
+2,125,593
+132% +$84.7M ﹤0.01% 1899
2021
Q3 		$61.9M Buy
1,614,173
+309,428
+24% +$9.96M ﹤0.01% 2518
2021
Q2 		$36.8M Buy
1,304,745
+1,006,289
+337% +$30.2M ﹤0.01% 2897
2021
Q1 		$9.86M Buy
298,456
+12,895
+5% +$452K ﹤0.01% 3582
2020
Q4 		$10.3M Buy
285,561
+188,358
+194% +$7.6M ﹤0.01% 3343
2020
Q3 		$3.29M Buy
+97,203
New +$3.54M ﹤0.01% 3745

Other funds holding HRMY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock's HRMY Position: Q2 2026 in Review

BlackRock increased its Harmony Biosciences (HRMY) stake by 0.45% in Q2 2026, buying an estimated $1.01M and bringing the position to 7,101,965 shares worth $259M. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

BlackRock first reported a position in HRMY in Q3 2020 and has held it in 24 quarters since. The position peaked at $268M in Q4 2022. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • BlackRock held 7,101,965 shares of Harmony Biosciences worth $259M as of Q2 2026.
  • BlackRock bought 31,930 Harmony Biosciences shares in Q2 2026, an estimated $1.01M.
  • Harmony Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1635 holding.
  • BlackRock first reported a position in Harmony Biosciences in Q3 2020 and has held it in 24 quarters since.
  • BlackRock's Harmony Biosciences position peaked at $268M in Q4 2022.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.